Abstract
Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.
Original language | English (US) |
---|---|
Pages (from-to) | 357-360 |
Number of pages | 4 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 31 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2018 |
Keywords
- ALL
- Acute lymphoblastic leukemia
- Allogeneic hematopoietic stem cell transplantation
- Ph+
- Philadelphia chromosome positive
- TKI
- Tyrosine kinase inhibitor
- allo-HSCT
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry